Ridaforolimus (MK-8669) synergizes with Dalotuzumab (MK-0646) in hormone-sensitive breast cancer.
BMC Cancer
; 16(1): 814, 2016 10 20.
Article
in En
| MEDLINE
| ID: mdl-27765027
Key words
Full text:
1
Collection:
01-internacional
Database:
MEDLINE
Main subject:
Breast Neoplasms
/
Sirolimus
/
Drug Synergism
/
Antibodies, Monoclonal
/
Neoplasms, Hormone-Dependent
Type of study:
Diagnostic_studies
/
Prognostic_studies
/
Risk_factors_studies
Limits:
Animals
/
Female
/
Humans
Language:
En
Journal:
BMC Cancer
Journal subject:
NEOPLASIAS
Year:
2016
Document type:
Article
Affiliation country:
Estados Unidos
Country of publication:
Reino Unido